Singapore Startup's Burn Treatment Needs No Refrigeration

Burn victims in remote areas and disaster zones just got a lifeline that doesn't need refrigeration or sterile facilities to work.

Bioactivx, a Singapore medical technology startup, launched Bioactiv Matrix on September 16. The synthetic skin substitute treats severe burns and deep wounds without using any animal materials.

Traditional skin substitutes rely on collagen from pigs or cows. They need cold storage and sterile environments, making them useless in emergency situations like earthquakes or floods where power is out and conditions are chaotic.

The new synthetic version changes that equation completely. It can be stored at room temperature and applied in the field, opening treatment possibilities for millions who previously couldn't access advanced burn care.

Bioactivx CEO Teo Peili says the product supports the body's natural healing without stem cells or growth factors. Early results show it may reduce infection, inflammation, and scarring compared to traditional treatments.

The company spun off from Singapore's A*STAR research agency and SingHealth healthcare cluster. It now operates from a 1,800 square foot facility where it 3D prints the synthetic skin locally.

Singapore's Health Sciences Authority already approved the product for use. The startup is now pursuing approval from the US Food and Drug Administration to expand access globally.

The Ripple Effect

Beyond burn victims, this technology could transform care for people who can't use animal-derived products due to religious or cultural reasons. Muslim and Hindu patients, along with vegans, now have an option that aligns with their values without compromising medical outcomes.

The startup raised $3 million in August, bringing total funding to $4.9 million. Swiss family office ContInvest and Singapore's Cocoon Capital led the recent round.

Bioactivx signed partnerships with Dutch manufacturer UltiMaker to scale production and Singapore's Novatech to deploy the technology in defense and humanitarian settings. The company aims for regional expansion by 2027.

Singapore MP Tin Pei Ling attended the launch and noted the product could significantly boost Singapore's biomedical sector, which produced over $32 billion worth of products in 2024. Research happening in Singapore today could heal burn victims worldwide tomorrow.

The team is already developing versions for chronic wounds, diabetic ulcers, and inflammatory skin conditions.

Innovation meets compassion when technology removes barriers between patients and healing.